Inflammatory markers may predict post-operative complications and recurrence in Crohn's disease patients undergoing gastrointestinal surgery.
Crohn's disease
gastro-intestinal surgery
outcomes
prognostic markers
Journal
ANZ journal of surgery
ISSN: 1445-2197
Titre abrégé: ANZ J Surg
Pays: Australia
ID NLM: 101086634
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
30
05
2022
received:
19
04
2022
accepted:
01
06
2022
pubmed:
24
6
2022
medline:
14
10
2022
entrez:
23
6
2022
Statut:
ppublish
Résumé
Most Crohn's Disease (CD) patients will require surgical intervention over their lifetime, with considerably high rates of post-operative complications. Risk stratification with reliable prognostic tools may facilitate clinical decision making in these patients. Blood cell interaction based inflammatory markers have proven useful in predicting patient outcomes in oncological and benign diseases. The aim of this study was to investigate their prognostic value in CD patients undergoing surgery. A retrospective single institution study of CD patients who underwent surgery between the years 2008 and 2019 was conducted. Data were collected from medical records and analysed for association of Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR) and the modified Systemic Inflammatory Score (mSIS) with post-operative outcomes. A total of 81 patients were included in the analysis. Half were females; mean age was 36 ± 15.54 years. Fifty seven percent (n = 46) were operated in expedited settings, with 23.5% developing post-operative complications. In elective patients, higher pre-operative NLR (P = 0.029) and PLR (P = 0.034) were associated with major post-operative complications, higher NLR (P = 0.029) and PLR (P = 0.034) were associated with re-operation and higher PLR correlated with Clavien-Dindo score (P = 0.032). In patients operated in expedited operations, higher pre-operative NLR (P = 0.021) and lower pre-operative LMR (P = 0.018) were associated with thromboembolic events and higher mSIS was associated with major post-operative complications (P = 0.032). Blood cell interaction based inflammatory markers confer an association with post-operative complications in CD patients undergoing surgery. These indices may facilitate patient selection and optimization when considering the risks and benefits of surgical interventions.
Sections du résumé
BACKGROUND
Most Crohn's Disease (CD) patients will require surgical intervention over their lifetime, with considerably high rates of post-operative complications. Risk stratification with reliable prognostic tools may facilitate clinical decision making in these patients. Blood cell interaction based inflammatory markers have proven useful in predicting patient outcomes in oncological and benign diseases. The aim of this study was to investigate their prognostic value in CD patients undergoing surgery.
METHODS
A retrospective single institution study of CD patients who underwent surgery between the years 2008 and 2019 was conducted. Data were collected from medical records and analysed for association of Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR) and the modified Systemic Inflammatory Score (mSIS) with post-operative outcomes.
RESULTS
A total of 81 patients were included in the analysis. Half were females; mean age was 36 ± 15.54 years. Fifty seven percent (n = 46) were operated in expedited settings, with 23.5% developing post-operative complications. In elective patients, higher pre-operative NLR (P = 0.029) and PLR (P = 0.034) were associated with major post-operative complications, higher NLR (P = 0.029) and PLR (P = 0.034) were associated with re-operation and higher PLR correlated with Clavien-Dindo score (P = 0.032). In patients operated in expedited operations, higher pre-operative NLR (P = 0.021) and lower pre-operative LMR (P = 0.018) were associated with thromboembolic events and higher mSIS was associated with major post-operative complications (P = 0.032).
CONCLUSIONS
Blood cell interaction based inflammatory markers confer an association with post-operative complications in CD patients undergoing surgery. These indices may facilitate patient selection and optimization when considering the risks and benefits of surgical interventions.
Identifiants
pubmed: 35733396
doi: 10.1111/ans.17852
pmc: PMC9796487
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2538-2543Informations de copyright
© 2022 The Authors. ANZ Journal of Surgery published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.
Références
Angiology. 2019 Oct;70(9):802-818
pubmed: 31030530
Gastric Cancer. 2019 Mar;22(2):403-412
pubmed: 29982861
Therap Adv Gastroenterol. 2020 Dec 21;13:1756284820979442
pubmed: 33425010
J Thorac Oncol. 2015 Feb;10(2):280-5
pubmed: 25299234
Int J Colorectal Dis. 2017 Jan;32(1):49-56
pubmed: 27785551
Thromb Haemost. 2009 Nov;102(5):916-24
pubmed: 19888530
Medicine (Baltimore). 2016 Jun;95(24):e3837
pubmed: 27310960
Mayo Clin Proc. 2017 Jul;92(7):1088-1103
pubmed: 28601423
Gastroenterology. 2013 Nov;145(5):996-1006
pubmed: 23896172
Sci Rep. 2017 Aug 16;7(1):8481
pubmed: 28814767
J Vasc Surg Venous Lymphat Disord. 2020 May;8(3):360-364
pubmed: 31405801
Am J Emerg Med. 2020 Mar;38(3):641-647
pubmed: 31785981
Blood. 2001 Nov 1;98(9):2720-5
pubmed: 11675343
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Surg Oncol. 2020 Dec;35:321-327
pubmed: 32977104
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
pubmed: 24793958
Int J Colorectal Dis. 2021 Mar;36(3):543-550
pubmed: 33236229
Medicine (Baltimore). 2019 Sep;98(38):e17215
pubmed: 31567977
Int J Surg. 2012;10(3):157-62
pubmed: 22361307
Vasa. 2018 Feb;47(2):143-147
pubmed: 29325504
J Orthop Surg Res. 2018 Aug 24;13(1):211
pubmed: 30143011
Br J Cancer. 2014 Jan 21;110(2):435-40
pubmed: 24357796
Shock. 2002 Dec;18(6):487-94
pubmed: 12462554
Am J Surg. 2021 Jan;221(1):117-121
pubmed: 32868026
Br J Cancer. 2015 Jun 30;113(1):150-8
pubmed: 26022929
JAMA. 2013 May 22;309(20):2150-8
pubmed: 23695484
J Gastrointestin Liver Dis. 2019 Jun 01;28:175-182
pubmed: 31204415
Ann Surg Oncol. 2019 Dec;26(13):4773-4781
pubmed: 31605344
Arch Surg. 1997 Dec;132(12):1263-9; discussion 1269-70
pubmed: 9403528
Gastroenterol Res Pract. 2017;2017:3526460
pubmed: 28798770
Nat Rev Gastroenterol Hepatol. 2016 Dec;13(12):707-719
pubmed: 27780971
Am Surg. 2022 Jan 03;:31348211069803
pubmed: 34979811
Int J Surg. 2018 Jul;55:128-138
pubmed: 29807167
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155772
Clin Chim Acta. 2018 Jun;481:142-146
pubmed: 29544747
Medicine (Baltimore). 2019 Aug;98(34):e16793
pubmed: 31441851
Int J Colorectal Dis. 2017 Dec;32(12):1663-1676
pubmed: 29051981
Gut. 2012 Apr;61(4):622-9
pubmed: 22267595
Int Angiol. 2018 Feb;37(1):4-11
pubmed: 28541022
Vasc Endovascular Surg. 2019 Jan;53(1):5-11
pubmed: 30021492
Ann Lab Med. 2019 Jul;39(4):345-357
pubmed: 30809980
Wien Klin Wochenschr. 2018 Jun;130(11-12):398-403
pubmed: 29435759
Gastroenterology. 2010 Oct;139(4):1147-55
pubmed: 20637205
ANZ J Surg. 2020 Oct;90(10):2041-2045
pubmed: 32856387